LakeShore Biopharma Files 6-K Report
Ticker: LSBWF · Form: 6-K · Filed: Oct 29, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Oct 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
LAKESHORE BIOPHARMA (LSPB) filed a 6-K, standard foreign issuer update.
AI Summary
LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on October 29, 2024. The filing is for the month of October 2024 and indicates the company is a foreign private issuer. LakeShore Biopharma is incorporated in E9 and has a fiscal year end of March 31.
Why It Matters
This filing provides an update on LakeShore Biopharma's status as a foreign private issuer, which can be relevant for investors tracking regulatory disclosures.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer status and does not contain significant new financial or operational information.
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- YS Biopharma Co., Ltd. (company) — Former Company Name
- YishengBio Co., Ltd (company) — Former Company Name
- 001-41598 (dollar_amount) — Commission file number
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a report of foreign private issuer for the month of October 2024, filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What are the former names of LakeShore Biopharma Co., Ltd.?
The company was formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd.
When did the company change its name from YS Biopharma Co., Ltd.?
The date of the name change from YS Biopharma Co., Ltd. was March 10, 2023.
What is the principal executive office address of LakeShore Biopharma?
The principal executive offices are located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
Does LakeShore Biopharma file annual reports under Form 20-F or Form 40-F?
LakeShore Biopharma indicates it files annual reports under Form 20-F.
Filing Stats: 243 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-10-29 09:16:00
Filing Documents
- ea0218949-6k_lakeshore.htm (6-K) — 12KB
- ea021894901ex99-1_lakeshore.htm (EX-99.1) — 5KB
- 0001213900-24-091446.txt ( ) — 18KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F INCORPORATION BY REFERENCE This current report on Form 6-K, including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into LakeShore Biopharma Co., Ltd’s registration statements on Form S-8 (File No. 333-279544 and File No. 333-273165 ) and to be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. 1 EXHIBITS Exhibit No. Description 99.1 Press Release – LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: October 29, 2024 3